169 Detection of non-metastatic non-small cell lung cancer in urine SUPPLEMENTAL MATERIALS Supplementary Table 1: Additional clinical data of surgical NSCLC patients of which pre- and postoperative methylation levels were evaluated for the detection of residual disease (patient 1 to 4) or disease recurrence (patient 5 to 14). Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Sampling Time first sample to surgery (days) 1 1 1 1 1 3 10 15 8 2 17 2 2 3 Time surgery to second sample (days) 6 5 6 5 973 578 326 309 277 278 236 252 223 63 Pathology Cancer stage* 1 3 1 1 1 1 1 1 1 3 1 3 3 2 Residual tumor classification (R) 0 0 0 0 0 0 0 0 0 0 0 1 0 0 Histology LUSC LUAD NOS LUAD LUSC LUAD LUAD LUAD LUAD LUAD LUAD LUAD LUAD LUAD Survival Disease free survival (days) - 101 492 257 1007 624 386 386 307 351 350 0 293 168 Total follow-up time (days) 979 132 874 389 1007 624 386 386 383 351 350 344 293 168 Alive Yes No Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes *Staging according the 8th edition of TNM criteria. LUAD = lung adenocarcinoma, LUSC = lung squamous cell carcinoma, NOS = carcinoma not otherwise specified, NSCLC = non-small cell lung cancer. 6
RkJQdWJsaXNoZXIy MjY0ODMw